type 2 diabetes glp 1 GLP-1 for Weight Loss and Liraglutide is a GLP-1 Receptor

If you've been wondering whether your Health Savings Account qualifies for these treatments, PlexusDx makes the answer clear: yes

These tests follow guidelines from organizations like the Substance Abuse and Mental Health Services Administration (SAMHSA)

article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)

Whether these effects are ultimately relevant to the long-term impact of such agents on the progression of kidney disease also seen in diabetes and obesity is not yet known

Additionally, individuals who are overweight, with a BMI of 27 or higher, and additional health issues may also qualify for GLP treatment

This finding is further supported by Gorenshtein et al